Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 36.1% | 88.4% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 88.6% | 64.6% | 88% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,151% | -1,434.8% | -2,671.9% | – |
| Net Income | $1 | -$0 | -$0 | $2 |
| % Margin | 1,845.9% | -1,312.6% | -1,627.8% | – |
| EPS Diluted | 11.64 | -6.33 | -4.23 | -6.36 |
| % Growth | 283.9% | -49.6% | 33.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |